Xenotransplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 Segmented By Animal Type (Pig, Rabbit, Baboon, Others), By Xeno Products (Organs, Tissues, Cells), By Organs (Kidney, Liver, Heart, Cornea, Others), By End Users (Transplants Center, Hospitals, Others), By Region

Global Xenotransplantation Market is expected to grow at a CAGR of 8.52% and reach USD 1289.11 million in 2031. This can be attributed to the rise in surgeries and improved understanding of immune system. Chronic kidney disease is a major public health issue in the United States, affecting over eight million people. When kidney function reaches a certain point, patients have end-stage renal disease and require dialysis or transplantation to live. More than 340,000 people are currently on dialysis, with 106,000 new patients added in 2019. Over 140,000 people had a functioning kidney transplant in the last 20 years, the prevalence of end-stage renal disease in these two populations has tripled. In 2020, medicare expenditures for end-stage renal disease are expected to exceed USD 28 billion.

Rise in Surgeries Increases the Demand for

Some of the factors that are likely to drive the growth of the xenotransplantation market include an increase in the volume of organ transplantation surgeries, an increase in the occurrence of chronic diseases, an increase in investment for the development of advanced and technical products, and an increase in the geriatric population. Changing lifestyles among the growing population, on the other hand, would increase numerous opportunities, which is expected to lead to a growth of xenotransplantation market throughout the forecast period.

Deceased donor kidney transplant was performed on 10,659 patients, while a live donor kidney transplant was performed on 6,432 patients. However, there are currently over 74,000 people on the national waiting list for a deceased donor kidney transplant. Even though the number of kidney transplants performed each year is increasing, the waiting list continues to grow. Every day, twelve people die while waiting for a kidney transplant.

Increasing demand for tissue and organ transplantation fuel the demand for Xenotransplantation

The global demand for organ transplantation has increased rapidly over the last decade due to an increase in the incidence of vital organ failure, rising success, and greater improvement in post-transplant outcome. However, the lack of sufficient organs for transplantation to meet current demand has resulted in major organ shortage crises. As a result, the number of patients on transplant waiting lists and the number of patients dying while on the waiting list has increased significantly.

Improved understanding of immune system to drive Global Xenotransplantation Market

Organ transplantation is one of the success stories of the second half of the twentieth century. Indeed, its success has resulted in the referral of an increasing number of patients, resulting in a scarcity of donor organs. Our better understanding of the immune system and the immune rejection process has resulted in the development of therapies that, in theory, will overcome the robust immune responses associated with xenogeneic tissue transplantation. In the coming years, human clinical trials using animal cells and organs to treat some of these diseases are expected to become a reality.

The introduction of advanced tissue products such as DeNovo NT also boost the Xenotransplantation Market

DeNovo NT Graft is a juvenile cartilage implant that is particulate and used to repair articular cartilage damage. Its purpose is to give surgeons an early-intervention option for articular cartilage repair.

Download Free Sample Report

Market Segmentation

The United States xenotransplantation market is expected to grow at a CAGR of 8.97% and reach 427.39 million in 2031.

Company Profiles

Major companies in the market are Novartis AG, Accord Healthcare, Pfizer, Inc, F. Hoffmann-La Roche Ltd., Terumo Medical Corporation,